Lunresertib Plus FOLFIRI Shows Safety, Elicits Responses in CCNE1+ or FBXW7+ Advanced GI Tumors
Liso-cel Shows Improved EFS, PFS, and Durable Responses in Second-line LBCL at 3 Years
Lutetium Lu 177 Dotatate Maintains PFS, ORR Benefits Across Subgroups in SSTR+ GEP-NETs
Dostarlimab/Chemo/Niraparib Generates PFS Benefit in Primary/Recurrent Endometrial Cancer